Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Kiniksa Pharmaceuticals International, plcKNSA · Entity 1954 | Chief Commercial Officer | December 31, 2020 | January 05, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Kiniksa Pharmaceuticals International, plc
Report date December 31, 2020 · Filed January 05, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common ShareSEC Table I · non-derivative | Direct | 5,176 |
Ending reported balance
After 2020-12-31 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2020-12-31 · Exercise / conversion · Acquired 7,337 · Balance 7,337 F1: Each Restricted Share Unit represents a contingent right to receive one Class A Common Share of the Issuer. Row 2 · 2020-12-31 · Tax withholding · Disposed 2,161 · Balance 5,176 |
| Restricted Share UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-12-31 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-12-31 · Exercise / conversion · Disposed 7,337 · Balance 0 F1: Each Restricted Share Unit represents a contingent right to receive one Class A Common Share of the Issuer. F2: The RSU will vest in a single installment on December 31, 2020, subject to the Reporting Person's continuous employment or service to the Issuer or any of its subsidiaries on the vesting date; there is no expiration date for the RSU. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Restricted Share Unit represents a contingent right to receive one Class A Common Share of the Issuer.
F2: The RSU will vest in a single installment on December 31, 2020, subject to the Reporting Person's continuous employment or service to the Issuer or any of its subsidiaries on the vesting date; there is no expiration date for the RSU.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 31, 2020 Filed Jan 5, 2021 22:07 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Unit · Derivative | 7,337 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-000197 · edgar.xml · derivative · entry 3 Rizvi Qasim · CIK 0001794636 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Share · 7,337 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Share Unit represents a contingent right to receive one Class A Common Share of the Issuer. F2 · derivative.exercise_date: The RSU will vest in a single installment on December 31, 2020, subject to the Reporting Person's continuous employment or service to the Issuer or any of its subsidiaries on the vesting date; there is no expiration date for the RSU. F2 · derivative.expiration_date: The RSU will vest in a single installment on December 31, 2020, subject to the Reporting Person's continuous employment or service to the Issuer or any of its subsidiaries on the vesting date; there is no expiration date for the RSU. Read SEC document |
| December 31, 2020 Filed Jan 5, 2021 22:07 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Tax withholdingClass A Common Share | 2,161 | $17.67 | $38,184.87 |
DisclosureSEC source: 0001179110-21-000197 · edgar.xml · nonDerivative · entry 2 Rizvi Qasim · CIK 0001794636 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,176 Read SEC document |
| December 31, 2020 Filed Jan 5, 2021 22:07 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Common Share | 7,337 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-21-000197 · edgar.xml · nonDerivative · entry 1 Rizvi Qasim · CIK 0001794636 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,337 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Share Unit represents a contingent right to receive one Class A Common Share of the Issuer. Read SEC document |
| September 10, 2020 Filed Sep 14, 2020 21:09 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantShare Option · Derivative | 75,000 | $0.00 Strike: $15.50 | $0.00 |
DisclosureSEC source: 0001179110-20-009720 · edgar.xml · derivative · entry 1 Rizvi Qasim · CIK 0001794636 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Class A Common Shares · 75,000 shares Expires 2030-09-09 F1 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in thirty-six equal monthly installments thereafter. The vesting commencement date is September 10, 2020. Read SEC document |
| March 13, 2020 Filed Mar 17, 2020 21:22 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantShare Option · Derivative | 75,000 | $0.00 Strike: $15.52 | $0.00 |
DisclosureSEC source: 0001179110-20-003834 · edgar.xml · derivative · entry 1 Rizvi Qasim · CIK 0001794636 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Class A Common Shares · 75,000 shares Expires 2030-03-12 F1 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in thirty-six equal monthly installments thereafter. The vesting commencement date is March 13, 2020. Read SEC document |
| December 12, 2019 Filed Dec 16, 2019 21:54 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantRestricted Share Units · Derivative | 7,337 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-012840 · edgar.xml · derivative · entry 1 Rizvi Qasim · CIK 0001794636 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,337 Underlying: Class A Common Shares · 7,337 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Share Unit represents a contingent right to receive one Class A Common Share of the Issuer. F2 · derivative.exercise_date: The Restricted Share Units will vest in a single installment on December 31, 2020, subject to the Reporting Person's continuous employment or service to the Issuer or any of its subsidiaries on the vesting date. F2 · derivative.expiration_date: The Restricted Share Units will vest in a single installment on December 31, 2020, subject to the Reporting Person's continuous employment or service to the Issuer or any of its subsidiaries on the vesting date. Read SEC document |
| December 06, 2019 Filed Dec 9, 2019 22:58 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantClass A Common Shares · Derivative | 30,000 | $0.00 Strike: $10.61 | $0.00 |
DisclosureSEC source: 0001179110-19-012551 · edgar.xml · derivative · entry 1 Rizvi Qasim · CIK 0001794636 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Class A Common Shares · 30,000 shares Expires 2029-12-05 F1 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in thirty-six equal monthly installments thereafter. The vesting commencement date is December 9, 2019. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.